Estrogen in prevention and treatment of osteoporosis.
Estrogen has clearly been shown to decrease bone loss and frequency of osteoporotic fractures. Calcitonin has been shown in several studies to reduce the rate of bone loss, although no data are yet available demonstrating a reduction in fracture frequency. Studies of osteoporosis intrinsically assume that prevention of further loss, or increments in bone mass, will be associated with declines in fracture recurrence. That may not always be the case. Recent controlled studies in which fluoride was used to increase bone mass in vertebral bodies resulted in no significant decline in fracture recurrence, and there was even a suggestion of increased fracture risk at some sites. Thus further data on calcitonin will be important, even though calcitonin is not expected to alter bone quality as does fluoride. Alternative therapies to calcitonin and estrogen are being investigated in clinical studies since both are currently limited in their use. Because calcitonin currently requires nearly daily injections, estrogen remains the principal agent available for both prevention and treatment in spite of its wide effect on multiple body systems. Bisphosphonates, given continuously or intermittently, appear to be relatively safe oral alternatives to calcitonin. The long-term effects of these agents need to be evaluated in greater detail before they can be recommended for prevention, but a role in therapy of the established disorder seems likely. The skeletal effect of bisphosphonates is also inhibition of bone remodeling and therefore prevention of further bone loss. Thus, they add nothing to the other therapeutic regimens from this perspective and as with calcitonin therapy, documentation of decreased frequency of fracture is lacking. Agents to increase bone mass are purely investigational at this time and many years may elapse before efficacy can be shown for such interventions.
Department of Internal Medicine, Helen Hayes Hospital, West Haverstraw, New York 10993.
R
R
Lindsay
F
F
Cosman
D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008855:Microscopy, Electron, Scanning; D015663:Osteoporosis, Postmenopausal / Q000473:pathology / Q000517:prevention & control* / Q000628:therapy